Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Antibiotics

Antibiotic developer Nabriva to wind down

by Michael McCoy
January 12, 2023 | A version of this story appeared in Volume 101, Issue 2

 

The structure of Xenleta (lefamulin).

Nabriva Therapeutics says it is going to wind down, becoming the latest antibiotic developer to fail commercially. Nabriva was formed in 2006 from Sandoz’s antibiotic research operations. The company discovered lefamulin in 2006 and won US Food and Drug Administration approval for it in 2019, launching the drug as Xenleta, but it was not able to amass significant sales. Nabriva says it will terminate all employees and seek a buyer for lefamulin. The antibiotic firms Melinta Therapeutics, Aradigm, and Achaogen all declared bankruptcy in 2019.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.